Jing Fan is the founder of Hopstem. Hopstem has raised $155M in total funding. Latest round: Series B. Backed by Lilly Asia Ventures.
Jing Fan is the founder and CEO of Hopstem, a company focused on developing induced pluripotent stem cell (iPSC) therapies for neurological disorders like stroke and traumatic brain injury. Founded in 2017, Hopstem operates a neural differentiation platform and a GMP manufacturing facility. The company has raised $154.5 million in total funding across multiple rounds, including a recent $40 million Series B round in November 2021.
Full founder directory · Investor directory · Company funding database · Fundraising library